Abstract
Head and neck squamous epithelial carcinogenesis is a complex multistep process that entails a progressive acquisition of alterations in diverse vital cellular pathways. The nature of these alterations and the order of their occurrence have remained unresolved. In the past 15 years, the thrust of research in this field has centered on the epithelial genetic and/or epigenetic changes attendant to their development and progression. Little efforts, however, have been expended on changes in structural or host microenvironment and their role in these tumors. Only recently has the latter topic become the focus of attention. This review will address recent advances in both cellular and structural findings in head and neck squamous carcinoma development and progression. Targeting these events for biological and therapeutic approaches is a desirable goal for future effective treatment of patients with this cancer.
Keywords: GSTP1 genotypes, DNA methylation, Epidermal Growth Factor, Angiogenesis, Epithelial-Mesenchymal Transformation, surrogate markers
Current Cancer Drug Targets
Title: Pathobiology of Head and Neck Squamous Tumorigenesis
Volume: 7 Issue: 7
Author(s): Adel K. El-Naggar
Affiliation:
Keywords: GSTP1 genotypes, DNA methylation, Epidermal Growth Factor, Angiogenesis, Epithelial-Mesenchymal Transformation, surrogate markers
Abstract: Head and neck squamous epithelial carcinogenesis is a complex multistep process that entails a progressive acquisition of alterations in diverse vital cellular pathways. The nature of these alterations and the order of their occurrence have remained unresolved. In the past 15 years, the thrust of research in this field has centered on the epithelial genetic and/or epigenetic changes attendant to their development and progression. Little efforts, however, have been expended on changes in structural or host microenvironment and their role in these tumors. Only recently has the latter topic become the focus of attention. This review will address recent advances in both cellular and structural findings in head and neck squamous carcinoma development and progression. Targeting these events for biological and therapeutic approaches is a desirable goal for future effective treatment of patients with this cancer.
Export Options
About this article
Cite this article as:
El-Naggar K. Adel, Pathobiology of Head and Neck Squamous Tumorigenesis, Current Cancer Drug Targets 2007; 7 (7) . https://dx.doi.org/10.2174/156800907782418338
DOI https://dx.doi.org/10.2174/156800907782418338 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets Dendrimer Based Formulation of Erlotiniib HCl: Development, Characterization and <i>In-Vitro</i> Evaluation
Pharmaceutical Nanotechnology Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Translational Research: A Future Strategy for Managing Squamous Cell Carcinoma of the Head and Neck?
Anti-Cancer Agents in Medicinal Chemistry Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters p53 as the Focus of Gene Therapy: Past, Present and Future
Current Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets MicroRNAs as Cancer Biomarkers
MicroRNA Anti-Galectin Compounds as Potential Anti-Cancer Drugs
Current Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction
Anti-Cancer Agents in Medicinal Chemistry Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?
Anti-Cancer Agents in Medicinal Chemistry Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases
Current Bioactive Compounds Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics Network Pharmacology Analysis of Molecular Mechanism of Curcuma longa L. Extracts Regulating Glioma Immune Inflammatory Factors: Implications for Precise Cancer Treatment
Current Topics in Medicinal Chemistry